Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.13
−$0.02 · -0.93%
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Latest quote
$2.13
−$0.02 · -0.93%
After-hours
$2.09
−$0.04 · -1.88%
Oct 8, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Day range
Current $2.13
52-week range
Current $2.13
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
9
Overpriced
Sentiment
72
Bullish
Risk
56
Elevated Risk
Momentum
90
Strong Up
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Day range
Current $2.13
52-week range
Current $2.13
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.65M USD | 13.63M USD | 63.53M USD | 96.3M USD | 55.85M USD |
| Cost of goods sold | 12.9M USD | 118.53M USD | 157.19M USD | 13.76M USD | 5.85M USD |
| Gross profit | −6.26M USD | −104.9M USD | −93.65M USD | 82.54M USD | 50M USD |
| Research and development | 107.83M USD | 135M USD | 172.6M USD | 320.45M USD | 215.52M USD |
| Selling, general, and administrative | 46.52M USD | 90.64M USD | 96.86M USD | 84.23M USD | 57.32M USD |
| Operating expenses | 141.45M USD | 105.38M USD | 96.86M USD | 390.93M USD | 266.99M USD |
| Interest income | 11.05M USD | 17.29M USD | 17.19M USD | 5.84M USD | 1.31M USD |
| Depreciation and amortization | 9.3M USD | 18.96M USD | 18.28M USD | 13.76M USD | 5.85M USD |
| Operating income | −147.7M USD | −210.28M USD | −190.51M USD | −308.39M USD | −216.99M USD |
| Net income | −136.32M USD | −186.26M USD | −160.93M USD | −281.72M USD | −212.15M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$5.63
164.32% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI7.63M0.00%2.3T USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF2.87M0.00%95.4B USD0.05%$233.13-0.15%
Schwab U.S. Small-Cap ETFSCHA1.18M0.01%21.7B USD0.03%$32.66+0.15%
iShares Micro-Cap ETFIWC771.49K0.06%1.32B USD0.60%$182.79-0.31%
Vanguard Health Care ETFVHT679.4K0.00%22B USD0.09%$313.85-0.46%
Invesco RAFI US 1500 Small-Mid ETFPRFZ523.57K0.02%2.65B USD0.36%$52.82+0.17%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM390K0.33%116.54M USD0.73%$15.90-0.44%
Avantis U.S. Small Cap Equity ETFAVSC310.85K0.01%3.04B USD0.25%$69.96+0.47%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFSchwab U.S. Small-Cap ETFSCHAiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAvantis U.S. Small Cap Equity ETFAVSCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
